Stem Cells, B Cells, and T Cells in Focus at CMSC

                                                                  

Cell-based therapies — and the role T and B cells play in the development of multiple sclerosis (MS) — are a few of the cutting-edge topics on the agenda at the upcoming Consortium of Multiple Sclerosis Centers (CMSC) 2016 Annual Meeting.

The meeting, being held June 1 to 4 in National Harbor, Maryland, brings together physicians, scientists, researchers, nurses, rehabilitation specialists, occupational therapists, social workers, and others involved in caring for patients with MS and trying to unlock the mysteries of the disease.

The Consortium, celebrating its 30th anniversary, has more than 200 member centers in the United States and Canada, representing 10,000 healthcare professionals who provide care for more than 200,000 individuals with MS and their families.

This year, CMSC expects some 2000 attendees, the organization’s chief executive officer, June Halper, MSN, APN-C, MSCN, told Medscape Medical News.

The meeting will be heavy on networking and educational programming, but there will also be platform and poster presentations of some 400 abstracts, including 5-year data on alemtuzumab in patients with active relapsing-remitting MS from the CARE-MS II study and phase 3 efficacy data on ocrelizumab in primary progressive MS.

Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews